Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Trial ID or NCT#
NCT02216409
Status
NOT RECRUITING
Purpose
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Official Title
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma
- Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.
- Adequate hematologic status
- Adequate coagulation function
- Adequate hepatic function
- Adequate renal function
Exclusion Criteria:
- Known primary tumors of central nervous system disease
- Known active brain metastases
- Known cardiopulmonary disease
Investigator(s)
A. Dimitrios Colevas, MD
Medical oncologist,
Head and neck specialist,
Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Branimir I. Sikic, M. D.
Youn H Kim, MD
Dermatologic oncologist,
Cutaneous oncology specialist,
Dermatologist
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Contact us to find out if this trial is right for you.
Contact
CCTO
1-650-498-7061
View on